Beverley Rowbotham
Board Member
Infectious Diseases
RCPAQAP
Australia
Biography
Dr Rowbotham trained in Haematology in Brisbane and at the Mayo Clinic, Rochester, Minnesota. While her MD was awarded for work in thrombosis research, she maintains an active interest in all areas of diagnostic haematology. She is Director of Haematology with Sullivan Nicolaides Pathology in Queensland. She is an Associate Professor of Pathology at the University of Queensland. She is a past President of the Royal College of Pathologists (2007-2009) and past President and Chair of the Association for Childhood Language and related Disorders (2001-2012). She currently holds the positions of Federal Councillor for the Australian Medical Association (Pathology craft group) and Clinical Lead of Pathology for the National E Health Transition Authority. She is the Chair of the National Pathology Accreditation Advisory Council. She is a member of the Medicare Benefits Schedule Review Taskforce. Dr Rowbotham is also a Director of the Avant Mutual Group, the AEIOU Foundation and Genome One.
Research Interest
Dr Rowbotham trained in Haematology in Brisbane and at the Mayo Clinic, Rochester, Minnesota. While her MD was awarded for work in thrombosis research, she maintains an active interest in all areas of diagnostic haematology. She is Director of Haematology with Sullivan Nicolaides Pathology in Queensland. She is an Associate Professor of Pathology at the University of Queensland. She is a past President of the Royal College of Pathologists (2007-2009) and past President and Chair of the Association for Childhood Language and related Disorders (2001-2012). She currently holds the positions of Federal Councillor for the Australian Medical Association (Pathology craft group) and Clinical Lead of Pathology for the National E Health Transition Authority. She is the Chair of the National Pathology Accreditation Advisory Council. She is a member of the Medicare Benefits Schedule Review Taskforce. Dr Rowbotham is also a Director of the Avant Mutual Group, the AEIOU Foundation and Genome One.